Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II‐targeting drugs

31 Jan 2006

Abstract excerpt

Twenty previously synthesized fused heterocyclic DNA-topoisomerase II (Topo II)-inhibiting compounds were investigated for their potential efficacy in various human cancer cell lines that were derived from different tumor entities. Moreover, different multidrug-resistant variants of these cancer cell lines with decreased Topo II expression were investigated. In parental, drug-sensitive cells merely the compounds...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bioactive Compounds and Antitumor Agents
Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16450374
DOI: 10.1002/ijc.21792

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II‐targeting drugsPMID 16450374Read ↗

Prediction of Broad Spectrum Resistance of Tumors towards Anticancer DrugsSemantic proximity Read ↗

Differential Targeting of Human Topoisomerase II Isoforms with Small MoleculesSemantic proximity Read ↗

Macrocyclic diterpenes resensitizing multidrug resistant phenotypes.Semantic proximity Read ↗

Recent developments in topoisomerase-targeted cancer chemotherapySemantic proximity Read ↗

Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeuticsSemantic proximity Read ↗

Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase InhibitorsSemantic proximity Read ↗

Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing.Semantic proximity Read ↗

Novel Approaches Towards Development of Non-Classical Platinum-Based Antineoplastic Agents: Design of Platinum Complexes Characterized by an Alternative DNA-Binding Pattern and/or Tumor-Targeted CytotoxicitySemantic proximity Read ↗

Novel camptothecin derivatives as topoisomerase I inhibitorsSemantic proximity Read ↗

Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitorsSemantic proximity Read ↗

Characterization of an etoposide-resistant human small-cell lung cancer cell line.Semantic proximity Read ↗

Etoposide: Discovery and Medicinal ChemistrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.